374
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Drug repurposing based novel anti-leishmanial drug screening using in-silico and in-vitro approaches

, , , &
Pages 10812-10820 | Received 08 Jun 2021, Accepted 26 Jun 2021, Published online: 11 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ahmed H. E. Hassan, Waleed A. Bayoumi, Selwan M. El-Sayed, Trong-Nhat Phan, Yeon Ju Kim, Chae Hyeon Lee, Soo Bin Cho, Taegeun Oh, Gyeongpyo Ham, Kazem Mahmoud, Joo Hwan No & Yong Sup Lee. (2023) Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now

Articles from other publishers (2)

Sabahat Yasmeen Sheikh, Waseem Ahmad Ansari, Firoj Hassan, Tabrez Faruqui, Mohammad Faheem Khan, Yusuf Akhter, Abdul Rahman Khan, Maqsood A. Siddiqui, Abdulaziz A. Al‐Khedhairy & Malik Nasibullah. (2023) Drug repositioning to discover novel ornithine decarboxylase inhibitors against visceral leishmaniasis. Journal of Molecular Recognition.
Crossref
Rafael Ferreira Dantas, Eduardo Caio Torres-Santos & Floriano Paes Silva Jr. (2022) Past and future of trypanosomatids high-throughput phenotypic screening. Memórias do Instituto Oswaldo Cruz 117.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.